Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer.

Parry MA, Srivastava S, Ali A, Cannistraci A, Antonello J, Barros-Silva JD, Ubertini V, Ramani V, Lau M, Shanks J, Nonaka D, Oliveira P, Hambrock T, Leong HS, Dhomen N, Miller C, Brady G, Dive C, Clarke NW, Marais R, Baena E.

Eur Urol Oncol. 2019 Feb;2(1):1-11. doi: 10.1016/j.euo.2018.08.005. Epub 2018 Sep 5.

2.

Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.

Fütterer JJ, Briganti A, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A.

Eur Urol. 2015 Dec;68(6):1045-53. doi: 10.1016/j.eururo.2015.01.013. Epub 2015 Feb 2. Review.

PMID:
25656808
3.

Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging.

Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, Maehara CK, Ahuja P, Faiena I, Pooli A, Salmasi A, Sisk A, Felker ER, Lu DSK, Reiter RE.

Eur Urol. 2019 May;75(5):712-720. doi: 10.1016/j.eururo.2018.11.031. Epub 2018 Dec 1.

PMID:
30509763
4.

Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.

Radtke JP, Takhar M, Bonekamp D, Kesch C, Erho N, du Plessis M, Buerki C, Ong K, Davicioni E, Hohenfellner M, Hadaschik BA.

Eur Urol Focus. 2018 Jul;4(4):540-546. doi: 10.1016/j.euf.2017.01.005. Epub 2017 Jan 26.

PMID:
28753844
5.

Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.

Pokorny MR, de Rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, Thompson LC.

Eur Urol. 2014 Jul;66(1):22-9. doi: 10.1016/j.eururo.2014.03.002. Epub 2014 Mar 14.

PMID:
24666839
6.

What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel.

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, Bolla M, Briers E, Cumberbatch MG, Fossati N, Gross T, Henry AM, Joniau S, van der Kwast TH, Matveev VB, van der Poel HG, De Santis M, Schoots IG, Wiegel T, Yuan CY, Cornford P, Mottet N, Lam TB, Rouvière O.

Eur Urol. 2017 Aug;72(2):250-266. doi: 10.1016/j.eururo.2017.02.026. Epub 2017 Mar 21. Review.

PMID:
28336078
7.

Multiparametric MRI in detection and staging of prostate cancer.

Boesen L.

Dan Med J. 2017 Feb;64(2). pii: B5327. Review.

PMID:
28157066
8.

Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?

Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, Campa R, Indino EL, Barchetti F, Sciarra A, Leonardo C, Gallucci M, Catalano C.

Eur Urol. 2018 Jul;74(1):48-54. doi: 10.1016/j.eururo.2018.03.007. Epub 2018 Mar 19.

PMID:
29566957
9.

Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy.

Sharma V, Nehra A, Colicchia M, Westerman ME, Kawashima A, Froemming AT, Kwon ED, Mynderse LA, Karnes RJ.

Eur Urol. 2018 Jun;73(6):879-887. doi: 10.1016/j.eururo.2017.11.012. Epub 2017 Nov 28.

PMID:
29195777
10.

Diagnostic Pathway with Multiparametric Magnetic Resonance Imaging Versus Standard Pathway: Results from a Randomized Prospective Study in Biopsy-naïve Patients with Suspected Prostate Cancer.

Porpiglia F, Manfredi M, Mele F, Cossu M, Bollito E, Veltri A, Cirillo S, Regge D, Faletti R, Passera R, Fiori C, De Luca S.

Eur Urol. 2017 Aug;72(2):282-288. doi: 10.1016/j.eururo.2016.08.041. Epub 2016 Aug 27.

PMID:
27574821
11.

Direct comparison of multiparametric magnetic resonance imaging (MRI) results with final histopathology in patients with proven prostate cancer in MRI/ultrasonography-fusion biopsy.

Borkowetz A, Platzek I, Toma M, Renner T, Herout R, Baunacke M, Laniado M, Baretton G, Froehner M, Zastrow S, Wirth M.

BJU Int. 2016 Aug;118(2):213-20. doi: 10.1111/bju.13461. Epub 2016 Apr 2.

12.

Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.

Radtke JP, Schwab C, Wolf MB, Freitag MT, Alt CD, Kesch C, Popeneciu IV, Huettenbrink C, Gasch C, Klein T, Bonekamp D, Duensing S, Roth W, Schueler S, Stock C, Schlemmer HP, Roethke M, Hohenfellner M, Hadaschik BA.

Eur Urol. 2016 Nov;70(5):846-853. doi: 10.1016/j.eururo.2015.12.052. Epub 2016 Jan 19.

PMID:
26810346
13.

What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?

De Visschere PJ, Naesens L, Libbrecht L, Van Praet C, Lumen N, Fonteyne V, Pattyn E, Villeirs G.

Eur Radiol. 2016 Apr;26(4):1098-107. doi: 10.1007/s00330-015-3894-x. Epub 2015 Jul 3.

PMID:
26135002
14.

Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL?

Pepe P, Garufi A, Priolo G, Pennisi M.

Clin Genitourin Cancer. 2015 Feb;13(1):e27-30. doi: 10.1016/j.clgc.2014.06.013. Epub 2014 Jun 21.

PMID:
25081324
15.

Outcomes of Serial Multiparametric Magnetic Resonance Imaging and Subsequent Biopsy in Men with Low-risk Prostate Cancer Managed with Active Surveillance.

Hsiang W, Ghabili K, Syed JS, Holder J, Nguyen KA, Suarez-Sarmiento A, Huber S, Leapman MS, Sprenkle PC.

Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30148-8. doi: 10.1016/j.euf.2019.05.011. [Epub ahead of print]

PMID:
31147263
16.

Confirmatory biopsy of men under active surveillance: extended versus saturation versus multiparametric magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy.

Pepe P, Cimino S, Garufi A, Priolo G, Russo GI, Giardina R, Reale G, Pennisi M, Morgia G.

Scand J Urol. 2017 Aug;51(4):260-263. doi: 10.1080/21681805.2017.1313310. Epub 2017 May 17.

PMID:
28513296
17.

Magnetic resonance imaging in prostate cancer detection and management: a systematic review.

Monni F, Fontanella P, Grasso A, Wiklund P, Ou YC, Randazzo M, Rocco B, Montanari E, Bianchi G.

Minerva Urol Nefrol. 2017 Dec;69(6):567-578. doi: 10.23736/S0393-2249.17.02819-3. Epub 2017 May 8. Review.

18.

Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.

Pessoa RR, Viana PC, Mattedi RL, Guglielmetti GB, Cordeiro MD, Coelho RF, Nahas WC, Srougi M.

BJU Int. 2017 Apr;119(4):535-542. doi: 10.1111/bju.13624. Epub 2016 Sep 3.

19.

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.

Brown LC, Ahmed HU, Faria R, El-Shater Bosaily A, Gabe R, Kaplan RS, Parmar M, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham A, Oldroyd R, Parker C, Bott S, Burns-Cox N, Dudderidge T, Ghei M, Henderson A, Persad R, Rosario DJ, Shergill I, Winkler M, Soares M, Spackman E, Sculpher M, Emberton M.

Health Technol Assess. 2018 Jul;22(39):1-176. doi: 10.3310/hta22390.

20.

A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.

Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, Hosking-Jervis F, Hindley RG, Lewi H, McCartan N, Moore CM, Nigam R, Ogden C, Persad R, Shah K, van der Meulen J, Virdi J, Winkler M, Emberton M, Ahmed HU.

Eur Urol. 2018 Oct;74(4):422-429. doi: 10.1016/j.eururo.2018.06.006. Epub 2018 Jun 28.

Supplemental Content

Support Center